June 2017
Volume 58, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2017
The effect of dexamethasone on myocilin, AXIN2 and sFRP1 expression in primary human trabecular meshwork cells
Author Affiliations & Notes
  • Jie J Zheng
    Department of Ophthalmology, Stein Eye Institute, UCLA, Los Angeles, California, United States
  • Sarah D Ahadome
    Department of Ophthalmology, Stein Eye Institute, UCLA, Los Angeles, California, United States
  • Elizabeth Tannous
    Department of Ophthalmology, Stein Eye Institute, UCLA, Los Angeles, California, United States
  • Chi Zhang
    Department of Ophthalmology, Stein Eye Institute, UCLA, Los Angeles, California, United States
  • Footnotes
    Commercial Relationships   Jie Zheng, None; Sarah Ahadome, None; Elizabeth Tannous, None; Chi Zhang, None
  • Footnotes
    Support  This work was supported in part by NIH grants GM100909 and by Research to Prevent Blindness.
Investigative Ophthalmology & Visual Science June 2017, Vol.58, 3489. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Jie J Zheng, Sarah D Ahadome, Elizabeth Tannous, Chi Zhang; The effect of dexamethasone on myocilin, AXIN2 and sFRP1 expression in primary human trabecular meshwork cells. Invest. Ophthalmol. Vis. Sci. 2017;58(8):3489.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To investigate how dexamethasone (Dex) affects the expression of myocilin mRNA, Axin2 mRNA and sFRP1 mRNA, over 10 days of treatment in primary human trabecular meshwork (TM) cells.

Methods : Primary human trabecular meshwork cells cultured from corneal scleral rims, were treated with 100 nM Dex or DMSO vehicle every day for 10 days. The RNA was isolated each day and quantitative PCR analysis was subsequently carried out for the expression of myocilin mRNA, AXIN2 mRNA and sFRP1 mRNA.

Results : Myocilin mRNA, AXIN2 mRNA and sFRP1 mRNA were all significantly up regulated in Dex treated cells compared to their vehicle counterparts. The increase of myocilin expression in Dex treated cells started at day 2; AXIN2 expression elevated around day 3, and sFRP1 expression increased around day 7. The highest point of expression of sFRP1 was observed between days 8 and 9 and this correlated with decreased AXIN2 expression.

Conclusions : : During the course of Dex treatment, there was increased expression of myocilin, AXIN2 and sFRP1 respectively in the TM cells. Myocilin is known to activate Wnt signaling in TM cells; expression of Axin2 is an established biomarker of the Wnt/β-catenin signaling; and sFRP1 is a negative regulator of the Wnt signaling pathway. We therefore propose that in the prolonged presence of Dex, heightened myocilin expression may over activate Wnt and the resultant increase in sFRP1 expression we also observed is suggestive of a regulatory mechanism against this uncontrolled Wnt signaling.

This is an abstract that was submitted for the 2017 ARVO Annual Meeting, held in Baltimore, MD, May 7-11, 2017.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×